Shearman Mark S 4
4 · Editas Medicine, Inc. · Filed Jun 16, 2021
Insider Transaction Report
Form 4
Shearman Mark S
EVP, Chief Scientific Officer
Transactions
- Award
Common Stock
2021-06-14+32,701→ 32,701 total - Award
Stock Option (right to buy)
2021-06-14+52,718→ 52,718 totalExercise: $38.53Exp: 2031-06-13→ Common Stock (52,718 underlying)
Footnotes (2)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 14, 2022 continuing through June 14, 2025.
- [F2]This option was granted on June 14, 2021 and is scheduled to vest over four years, with 25% of the shares to vest on June 14, 2022 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 14, 2025.